About Achromatopsia
Achromatopsia is a congenital, stationary (non-progressive) retinal disorder caused by the complete absence of functional cone photoreceptors, resulting in total colour blindness, severely reduced visual acuity, extreme light sensitivity, and nystagmus from birth. The most common causative genes, CNGA3 and CNGB3, encode subunits of the cyclic nucleotide-gated channel essential for phototransduction in cone cells. Because the cone cells themselves are often structurally preserved despite being non-functional, gene therapy approaches aimed at restoring cone function have shown considerable promise in early-phase clinical trials.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Achromatopsia trials.
Gene-specific eligibility is strict; CNGA3 and CNGB3 trials are separate programmes, so molecular confirmation of your specific pathogenic variant is mandatory.
Foveal cone structure assessed by adaptive optics or high-resolution OCT is used to determine whether sufficient residual cone cells remain to benefit from gene therapy; recent imaging is important.
Trials may cap enrolment by age, often preferring younger patients; contact trial coordinators early as paediatric cohorts can fill quickly.
Patient Resources
Find recruiting Achromatopsia trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Achromatopsia. Updated daily.